Close Menu Phone
JaneS 369

About Jane

Jane Sheridan practises in commercial and corporate law, with a particular focus on public company and insolvency matters. Involved in the privatisation of some of Australia’s largest publicly held assets, Jane has acted for equity investors in the acquisition of major infrastructure assets within the transport and electricity industries.

Jane's experience encompasses a wide range of corporate transactions, equity capital markets, M&A and regulatory compliance. Jane is recognised by Best Lawyers® International  in the area of corporate law, M&A and insolvency and reorganisation law and is recommended for capital markets, corporate and M&A and restructuring and insolvency by The Legal 500 Asia Pacific. Jane is also recognised in Chambers Asia Pacific  in the category of restructuring/insolvency.  

In addition to her public company and insolvency work, Jane acts for a number of clients involved in the biotechnology sector, advising on commercialisation and other transactional matters. Jane was a member of the Takeovers Panel, a peer body which reviews corporate control transactions and resolves takeover disputes, from 2010 – 2016. She was a commercial partner at Arnold Bloch Leibler between 1995 and 2018.

Practice focus

Jane is a member of the commercial & corporate, insolvency, intellectual property and technology practices.  Her practice focuses on the following areas:
  • public listings and capital raisings, both on behalf of issuers and underwriters, including advice on Corporations Act regulatory requirements and Australian Stock Exchange (ASX) listing rule compliance;
  • infrastructure privatisation and major projects, including project documentation and structuring of equity participation;
  • corporate transactions and M&A, including sales and purchases of businesses, joint ventures, shareholders and subscription agreements, supply/distribution and other services agreements;
  • insolvency, including restructures and realisations involving complex corporate groups and managed investment schemes;
  • biotechnology, commercialisation and licensing, venture capital funds, research and development; and
  • corporate governance, licensing and regulatory compliance.


Snapshot of major assignments:

  • Longtable Group: in relation to its $43 million capital raising and acquisition of B-d. Farm Paris Creek, one of Australia’s leading organic biodynamic dairy food and beverage businesses;
  • Nulac Food: in relation to the 100% sale of Australia’s leading producer of goat milk products to ASX listed Bubs Australia;
  • TPI Enterprises Limited: in relation to its $44 million placement and entitlement offer;
  • Maggie Beer Products: in relation to the acquisition by Primary Opinion Ltd of a 49% stake;
  • Hazel Hill Pty Ltd: in relation to its off-market takeover offer for Truffle Properties Limited;
  • Vector Limited: in relation to its advanced electricity metering services agreement with Origin Energy;
  • TPI Enterprises Limited: in relation to its capital raising and listing on ASX;
  • Hydration Pharmaceuticals Trust: in relation to its $85 million sale of its Hydralyte business in Australia and New Zealand to Prestige Brands;
  • Fonterra: in relation to the sale of its Australian yoghurt and dairy desserts business to Parmalat Australia;
  • Tomizone Limited: in relation to its reverse takeover of PHW Consolidated and backdoor listing on ASX;
  • Premier Investments: in relation to its successful $900 million takeover of the Just Group;
  • The equity investors: in the $5.6 billion acquisition of Sydney Airport and the equity investors in each of the successful consortia in the acquisition of the Brisbane, Adelaide and Coolangatta Airports;
  • The equity investors and equity underwriters: to the successful consortia in relation to the $4.8 billion acquisition of the Loy Yang A power station and mine and in relation to the $2.4 billion acquisition of the Hazelwood power station and mine;
  • The equity underwriters: to the successful consortia in relation to the $4.9 billion Brisbane Airport Link, the $3.88 billion EastLink Project and the $1.8 billion CityLink Project;
  • Acrux: in relation to its exclusive worldwide licensing agreement with US pharmaceutical giant, Eli Lilly, including US $335 million in milestones and worldwide royalties; and
  • Liquidators of Timbercorp: in relation to the effect of the Timbercorp group’s insolvency on the forestry and horticultural managed investment schemes operated by Timbercorp.

Recognition & publications

Take a look at Insights & News articles referencing Jane Sheridan